Stocks Health care EBS
NYSE · Health careEmergent BioSolutions Inc. (EBS)
Emergent BioSolutions Inc. brought in $649.1M of revenue over the twelve months to September 30, 2026, down 17.7% from a year earlier. It posted a net loss of $260.7M. Operating cash flow minus capital spending left $156.8M of free cash flow in fiscal 2025. At September 30, 2026 it held $175.7M in cash against $514.3M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 3, 2026.
Key facts about Emergent BioSolutions Inc.
- Net worth
- Emergent BioSolutions Inc. has a market value (market cap) of $312.8M at the latest share price, and shareholders' equity of $313.2M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $742.9M (-28.8% year on year), with net income of $52.6M. Over the 12 months to September 30, 2026: revenue $649.1M, net loss $260.7M.
- Cash flow
- In fiscal 2025 operations brought in $170.6M of cash; after $13.8M of capital spending, free cash flow was $156.8M.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 3, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Emergent BioSolutions Inc.'s next report is expected around February 25, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Emergent BioSolutions Inc. does
Emergent BioSolutions Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NYSE under the ticker EBS.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $742.9M | $52.6M | $0.93 | $156.8M |
| 2024 | $1B | -$190.6M | -$3.60 | $35.8M |
| 2023 | $1B | -$760.5M | -$14.85 | -$257.9M |
| 2022 | $1.1B | -$211.6M | -$4.22 | -$149.9M |
| 2021 | $1.8B | $219.5M | $4.06 | $96.1M |
| 2020 | $1.6B | $305.8M | $5.68 | $395M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where EBS ranks in Health care
Latest SEC filings
What Emergent BioSolutions Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 4, 2026Other event 8-K
- November 3, 2026Quarterly report 10-Q · period to September 30, 2026Revenue fell 52% to $110M versus the same quarter last year; diluted EPS -$0.64 versus $0.91.
- November 2, 2026
- October 16, 2026
- September 14, 2026
- September 1, 2026Other event 8-K
- August 14, 2026Passive stake (5% or more) SCHEDULE 13G
- August 6, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 66% to $234.3M versus the same quarter last year; diluted EPS -$3.49 versus -$0.22.
- August 5, 2026
- July 31, 2026Passive stake changed SCHEDULE 13G/A
What is EBS worth? A DCF from its reported cash flow
Insider trades
What the people running Emergent BioSolutions Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $145.8K worth of shares in the last 90 days and bought none on the open market. All of the selling was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| October 7, 2026 | DeGolyer Donald WDirector | Soldpre-planned (10b5-1) | 17,800 | $126.2K |
| October 1, 2026 | Williams Paul AnthonySVP, Products Business | Soldpre-planned (10b5-1) | 3,000 | $19.6K |
| July 1, 2026 | Williams Paul AnthonySVP, Products Business | Soldpre-planned (10b5-1) | 3,000 | $25.2K |
| June 8, 2026 | Lindahl Richard SEVP, Chief Financial Officer | Shares withheld for tax | 3,964 | $31.7K |
| June 8, 2026 | Glessner ColeenEVP, Quality & Ethics, and CPL | Shares withheld for tax | 2,018 | $16.1K |
| June 8, 2026 | Williams Paul AnthonySVP, Products Business | Shares withheld for tax | 694 | $5.6K |
| June 8, 2026 | Hartzel WilliamSVP, Bioservices | Shares withheld for tax | 1,741 | $13.9K |
| May 1, 2026 | Dayal Sujata TyagiDirector | Soldpre-planned (10b5-1) | 12,781 | $106.8K |
Who owns EBS
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Oak Hill Advisors, L.P.13G, passive | 6.39% | November 13, 2024 |
| American Century Investment Management, Inc.13G, passive with 3 related filers | 5.4% | August 14, 2026 |
| Dimensional Fund Advisors LP13G, passive | 5.3% | April 9, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 195 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| BlackRock, Inc. | 4,716,599 | +375,137 |
| Dimensional Fund Advisors LP | 3,076,646 | +319,488 |
| State Street Corp | 2,929,238 | +79,537 |
| American Century Companies Inc | 2,770,448 | +344,726 |
| Vanguard Capital Management LLC | 2,198,839 | -59,156 |
| Geode Capital Management, LLC | 1,337,243 | +64,334 |
| Charles Schwab Investment Management Inc | 1,200,791 | -305,284 |
| Oak Hill Advisors LP | 1,113,338 | 0 |
| Millennium Management LLC | 1,072,185 | +540,184 |
| Ancora Advisors LLC | 1,067,867 | +658,600 |
| Aqr Capital Management LLC | 1,041,151 | +51,474 |
| Goldman Sachs Group Inc | 1,035,421 | +223,861 |
| Vanguard Portfolio Management LLC | 1,029,371 | -87,907 |
| D. E. Shaw & Co., Inc. | 900,108 | -103,804 |
| Russell Investments Group, Ltd. | 859,482 | +523,584 |
| Federated Hermes, Inc. | 831,125 | +374,806 |
| Prudential Financial Inc | 805,895 | +357,080 |
| Prescott Group Capital Management, L.L.C. | 772,771 | 0 |
| Renaissance Technologies LLC | 683,247 | +27,200 |
| Northern Trust Corp | 621,473 | +20,561 |
Insiders
16 insiders reported holding 2,720,885 shares in total, about $16.6M at the last price.
| Holder | Shares |
|---|---|
| Papa Joseph CPresident and CEO, Director | 493,153 |
| Lindahl Richard SEVP, Chief Financial Officer | 374,083 |
| Glessner ColeenEVP, Quality & Ethics, and CPL | 202,201 |
| Hartzel WilliamSVP, Bioservices | 185,558 |
| Lowry Simon CSVP, R&D, CMO | 177,914 |
| Perl JessicaSVP, General Counsel, Corp Sec | 165,286 |
| Fowler Neal FranklinDirector | 160,847 |
| Williams Paul AnthonySVP, Products Business | 156,098 |
| Harsanyi ZsoltChairman, Director | 149,076 |
| Richard RonaldDirector | 123,761 |
Questions about EBS
What does Emergent BioSolutions Inc. do?
Emergent BioSolutions Inc. is a company in the Health care sector, listed on NYSE as EBS. Its shares trade on NYSE under the ticker EBS.
What is Emergent BioSolutions Inc.'s net worth?
Emergent BioSolutions Inc. has a market value (market cap) of $312.8M at the latest share price, and shareholders' equity of $313.2M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Emergent BioSolutions Inc. profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $260.7M on revenue of $649.1M.
How much revenue does Emergent BioSolutions Inc. make?
Over the twelve months to September 30, 2026 Emergent BioSolutions Inc. reported revenue of $649.1M. That is 17.7% less than a year earlier.
When did Emergent BioSolutions Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 3, 2026. It covers the period to September 30, 2026. Its newest filing of any kind is the other event from November 4, 2026.
When is Emergent BioSolutions Inc.'s next earnings report?
Emergent BioSolutions Inc.'s next report is expected around February 25, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare EBS with
Follow EBS
Get an email when Emergent BioSolutions Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Emergent BioSolutions Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.